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Abstract
Background: Site-directed mutagenesis is a widely-used technique for introducing mutations into
a particular DNA sequence, often with the goal of creating a point mutation in the corresponding
amino acid sequence but otherwise leaving the overall sequence undisturbed. However, this
method provides no means for verifying its success other than sequencing the putative mutant
construct: This can quickly become an expensive method for screening for successful mutations.
An alternative to sequencing is to simultaneously introduce a restriction site near the point
mutation in manner such that the restriction site has no effect on the translated amino acid
sequence. Thus, the novel restriction site can be used as a marker for successful mutation which
can be quickly and easily assessed. However, finding a restriction site that does not disturb the
corresponding amino acid sequence is a time-consuming task even for experienced researchers. A
fast and easy to use computer program is needed for this task.
Results: We wrote a computer program, called SiteFind, to help us design a restriction site within
the mutation primers without changing the peptide sequence. Because of the redundancy of genetic
code, a given peptide can be encoded by many different DNA sequences. Since the list of possible
restriction sites for a given DNA sequence is not always obvious, SiteFind automates this task. The
number of possible sequences a computer program must search through increases exponentially
as the sequence length increases. SiteFind uses a novel "moving window" algorithm to reduce the
number of possible sequences to be searched to a manageable level. The user enters a nucleotide
sequence, specifies what amino acid residues should be changed in the mutation, and SiteFind
generates a list of possible restriction sites and what nucleotides must be changed to introduce that
site. As a demonstration of its use, we successfully generated a single point mutation and a double
point mutation in the wild-type sequence for Krüppel-like factor 4, an epithelium-specific
transcription factor.
Conclusion: SiteFind is an intuitive, web-based program that enables the user to introduce a novel
restriction site into the mutated nucleotide sequence for use as a marker of successful mutation.
It is freely available from http://www.utmb.edu/scccb/software/sitefind.html
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Background
There are several methods available for mutagenesis: 1) to
isolate single strand template DNA and then create the
mutation with one complementary primer [1]; 2) design
two sets of PCR primers that overlap the mutation site,
amplify the template by two PCR reactions and then clone
the two PCR fragments and the vector by three piece liga-
tion [2]; 3) Site-directed mutagenesis using the Quik-
Change method [3-5]. All of these in vitro mutagenesis
methods require careful design of one or more primers
that cover the mutation site. Currently, QuikChange site-
directed mutagenesis is the method of choice. This
method requires two complementary oligonucleotide
primers flanking the desired mutated nucleotide on both
the sense and anti-sense strands. Furthermore, each
primer must contain one to several base-pair changes
within the desired region. PCR is then performed using
these primers along with the gene of interest, which was
previously inserted into a vector containing an antibiotic
resistance gene. The extension step of the polymerase
chain reaction is given sufficient time to replicate the
entire circular DNA construct, with the reaction eventually
ending where it started. After several rounds of PCR, the
resulting mixture of newly-synthesized mutant constructs
and template DNA is incubated with a methylation-spe-
cific endonuclease to remove the wild-type template DNA
which contains methylated nucleotides. The mixture is
then transformed into competent bacteria, plated on an
antibiotic-containing medium, and grown overnight to in
order to allow individual colonies to grow.
However, since the bacteria was transformed with a com-
plex mixture of undigested template DNA, successful
point mutant copies of the template, and PCR side-prod-
ucts, it becomes difficult to determine which colonies
contain the desired mutant construct. Restriction enzyme
digestion of plasmid DNA extracted from each colony can
differentiate between correct and aberrant PCR products,
but it cannot distinguish between bacteria transformed
with template DNA and bacteria transformed the with
desired point mutant. Instead, plasmid DNA extracted
from each colony must be sent to a sequencing laboratory
and the sequence manually scanned for a successful muta-
tion. If the number of colonies containing template DNA
is high relative to the total number of colonies, this can be
an expensive and time-consuming process.
A simple method to confirm the presence of a point muta-
tion prior to sequencing is to design the mutation of the
sequence such that it introduces a novel restriction site,
taking advantage of the redundancy of the genetic code [6-
8]. Thus plasmid DNA extracted from each colony can be
digested with the appropriate restriction enzyme and then
run on a DNA gel to check for the presence of a band not
found in the template DNA. However, finding the correct
set of mutations to the DNA sequence in order to intro-
duce a restriction site without disturbing its correspond-
ing amino acid sequence is not always a trivial task,
requiring the investigator to manually generate hundreds
of possible DNA sequences and then scan them for restric-
tion sites. Even for an experienced molecular biologist, it
will take time and luck to find a suitable site. SILMUT, a
program written and published several years ago, can be
used to discover such diagnostic restriction sites [9]. The
user enters a short amino acid sequence, and SILMUT
determines if any of 30 of the most common, 6 bp restric-
tion sites can introduced within that sequence. To make
this task much faster and less error-prone, we wrote our
own, web-based computer program, called SiteFind.
In some cases, however, silent mutations in the coding
sequence can have a drastic effect on the translation rate.
Thus, the user must be alert to the possibility of codon
bias in the organism where this sequence will be
expressed.
Implementation
SiteFind overview
The ultimate goal of SiteFind is to search a given nucle-
otide sequence for any possible restriction sites that can be
introduced without disturbing the amino acid sequence
that it codes for. For example, the sequence CTCGAA
codes for the amino acid sequence LE, or leucine-gluta-
mate, but does not possess any common restriction site.
However, by simply changing the last Adenine to a Gua-
nine, the sequence becomes CTCGAG, which is the restric-
tion site for XhoI. At the same time, the amino acid
sequence is preserved, since both GAA and GAG code for
glutamate. For such a short sequence, the necessary muta-
tions to introduce a restriction site may be obvious, but
SiteFind can quickly search through much longer
sequences, where potential restriction sites may be hidden
in long sequence of nucleotides. We found that on the
average end-user personal computer, SiteFind can handle
sequences of up to approximately 400 bp.
SiteFind was designed with the purpose of introducing a
restriction site into a nucleotide sequence as a marker for
successful point mutation via site-directed mutagenesis.
Consistent with this purpose, the user can specify which
amino acids should be changed in the peptide sequence
and then select the potential restriction site closest to the
point mutation. Ideally, these two will overlap, but this is
not always possible. A novel restriction site within a few
nucleotides of the point mutation is often sufficient to use
as a marker.
Algorithm optimizations
The redundancy in the genetic code means that as the
length of a given amino acid sequence increases, theBMC Molecular Biology 2005, 6:22 http://www.biomedcentral.com/1471-2199/6/22
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number of possible DNA sequences that can code for that
sequence increases exponentially. Since the amino acid
serine can be represented by six different codons, this
means that a sequence of four serines can be represented
by 64 (1296) different DNA sequences. To substantially
reduce the number sequences to scan by our program,
SiteFind uses a "moving window" algorithm (See Fig. 1A).
The "moving window" algorithm effectively breaks up a
long nucleotide sequence into a series of short, non-
redundant sequences that can be then searched individu-
ally. Thus, a long amino acid sequence with millions of
possible nucleotide sequences can be converted into 10 or
so "windows", each with only a few hundred possible
sequences.
The size of each "window" is determined by the length of
the longest restriction site the user is searching for. In gen-
eral, for a given restriction site of n nucleotides, the win-
dow must be at least 2n-1 nucleotides long. SiteFind then
shifts the window only enough to ensure overlap between
windows such that any possible restriction site is found,
meaning that the window is shifted forward no more than
n nucleotides (See Fig. 1B). This process is then repeated
until the entire nucleotide sequence is traversed.
SiteFind was originally written in C++ as a simple com-
mand-line tool for in-house use. We subsequently rewrote
the program as a Java applet embedded in a HTML web
document, giving it a more intuitive, graphical interface
and posted it on our institutional website. The source
code to our Java applet is freely available and is released
under the GPL [10]. SiteFind was written using TextPad
v4.7.3 [11] and compiled with the Java 1.4.2 SDK [12].
The website was designed with Microsoft FrontPage.
Results
Using sitefind
SiteFind was designed to have an intuitive interface, with
each step necessary to specify the search conditions pre-
sented in a separate window. A button labeled "Next" at
the bottom right hand corner of each window allows the
user to progress to the next step. The SiteFind applet loads
in a browser once its webpage is visited and prints out a
simple message identifying the program name and crea-
tor. To begin, the user clicks "Next". The first window
prompts the user to enter a short segment (preferably at
least 15 nucleotides) of the wild-type DNA sequence, cov-
ering the region where a mutation is desired. The user is
then prompted to select the correct reading frame for the
sequence. After clicking "Next", the properly translated
sequence is given, as shown in Fig. 2A, The user then dou-
ble-clicks the amino acid he wishes to mutate and selects
from a drop-down list which residue it should be changed
to. If the user wishes to mutate more than one amino acid,
he can simply repeat this step. Each mutation is high-
lighted in red. In the next window, the user can select
which restriction sites the program should search for. Cur-
rently, SiteFind has 131 restriction sites to choose from
and uses them all by default, but the user is free to remove
any of these or add new ones if so desired. Any restriction
sites present in the wild-type sequence are removed from
the search. The next window then displays a progress bar
as it searches: in most cases, the search takes no more than
a few seconds. Once finished, the user can click "Next"
one last time, and the results are printed in a list. A list of
potential restriction sites is given, For each site, the wild-
type sequence displayed, with the necessary mutant
sequence displayed just under it. Any differences between
the two sequences are indicated. Below the mutant
sequence, the location of the introduced restriction site is
clearly marked. If there are multiple locations in the
sequence where a given restriction site can be introduced,
only the location closest to the desired point mutation is
displayed. (See Fig. 2B). The user can then use this infor-
mation to design the appropriate primers for performing
site-directed mutagenesis.
Examples of its use
We used this tool routinely in our laboratory. For exam-
ple, Krüppel-like factor 4 (KLF4) is a transcription factor
implicated in colon cancer. Previous studies on KLF4 have
shown that a single point mutation, R390S, can abolish its
ability to enter the nucleus, where it is normally exclu-
sively located [13,14]. In order to make such a construct,
we entered the wild-type DNA sequence corresponding to
amino acids 385–393 into SiteFind and then specified the
Moving window algorithm Figure 1
Moving window algorithm. a) Example of how the algo-
rithm is implemented with a 4 nucleotide restriction site. 
Each window is therefore 7 nucleotides and each successive 
window is shifted forward 4 nucleotides, ensuring minimal 
overlap. b) Example of all the possible sequences generated 
for each of the first two search windows using the moving 
window algorithm.BMC Molecular Biology 2005, 6:22 http://www.biomedcentral.com/1471-2199/6/22
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desired mutation R390S. Using the default settings, Site-
Find found 10 restriction sites that we could use as a
marker. We chose BglII since no BglII site was present in
our original construct, and it required the mutation of
only three nucleotides. Using this information, we were
then able to design the proper primers for site-directed
mutagenesis.
After transformation of competent bacteria with the PCR
product, we plated the cells on ampicillin-containing agar
overnight. We then picked several colonies and isolated
their plasmid DNA. The plasmid DNA was then digested
with ClaI, which is present in the vector backbone, and
BglII. Since BglII is neither present within the vector back-
bone nor the wild-type KLF4 sequence, BglII should only
cut successfully mutated plasmid DNA, yielding a 1244
bp fragment (See Fig. 3A). As shown in Fig. 3B, wild-type
plasmid DNA yields only one fragment, whereas success-
fully mutated DNA yields a second, 1.2 kb fragment.
To confirm that our mutant construct is expressed, we
transfected 293T cells, lysed the cells 48-hours post-trans-
fection, and performed an α-Flag Western blot with the
lysate. Fig. 3C demonstrates that both the wild-type and
mutant constructs express a protein of identical size,
whereas transfection with an empty vector yields no Flag-
tagged protein whatsoever. This is expected since a point
mutation should have no detectable effect on the molecu-
lar weight. Finally we verified the mutant construct by
sequencing (See. Fig. 3D).
To demonstrate that SiteFind can be used to design multi-
ple point mutation, we produced a double point muta-
tion of KLF4, mutating two successive lysines (K225/
K229) to arginine. Using SiteFind, we decided to intro-
duce an NheI site just 3' to the second point mutation.
After PCR and plasmid purification, we digested the
mutant construct with NheI and EcoRI. NheI should only
cut the mutant construct, producing a 767 bp fragment
(See Fig. 4A). As expected NheI cuts the mutant construct
to produce a second fragment of approximately 750 bp,
whereas the wild-type plasmid yields only one fragment
(See Fig. 4B). We confirmed expression of this construct in
293T cells, and as expected, both wild-type and K225/
229R mutant KLF4 produce bands of identical size (See
Fig. 4C). Finally, we verified our construct by sequencing
(See Fig. 4D).
Discussion
There are several programs available for designing primers
for site-directed mutagenesis. Most of these programs are
used to calculate the annealing temperature and to predict
secondary structures. They cannot be used to design a
restriction site. SiteFind is designed specifically for this.
In an easy-to-use, graphical interface, the user is prompted
to enter the desired template nucleotide sequence. Then,
the translated amino acid sequence is given and the user
is able to select which amino acids to mutate. After that,
the user can specify which restriction sites to search for,
and even add additional sites if so desired. Finally, after a
few seconds, a list of potential restriction sites is given. For
each site, only the location closest to the desired point
mutation and involving the fewest number of mutations
is given. This substantially reduces the amount of infor-
mation the user has to process prior to selecting the opti-
mal sequence for site-directed mutagenesis, saving both
time and money. Furthermore, SiteFind can be used for
any type of mutagenesis and places no limits on the
number of point mutations in the mutant sequence.
As the sequence length increases, when simply generating
every possible nucleotide sequence for a given amino acid
sequence and then searching for the presence of a restric-
tion site, the time required for the search increases expo-
nentially. If done in this manner, searches of longer than
15 bp quickly become infeasible. Our "moving window"
algorithm is a novel way to drastically reduce the time
SiteFind Screenshots Figure 2
SiteFind Screenshots. a) Sample input, showing translated 
nucleotide sequence and a mutant residue highlighted in red. 
b) Sample output, showing a novel BglII site discovered 
within the sequence.BMC Molecular Biology 2005, 6:22 http://www.biomedcentral.com/1471-2199/6/22
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required for a search, and yet does so without missing any
potential sites. Because SiteFind implements this algo-
rithm, it can process sequences up to 400 bp.
Shankarappa et. al. have published a computer program
called SILMUT [9]. SILMUT is a simple command-line
program that can search a short amino acid sequence for
the 30 most common, 6 bp restriction sites. It does this by
translating each restriction site in all three frames and
compares every possible translation with the user-speci-
fied amino acid sequence. During preparation of this
manuscript, we discovered another web-based program
that performs a function similar to SiteFind, called the
Primer Generator [15]. However, the Primer Generator
requires the user to manually type in both the wild-type
sequence and desired mutant amino acid sequence and to
KLF4 R390S mutant has a novel BglII restriction site Figure 3
KLF4 R390S mutant has a novel BglII restriction site. a) pCS2-KLF4-R390S construct diagram. b) ClaI / BglII Restriction 
digest of both wild-type and successfully mutated plasmid DNA. c) α-Flag Western blot showing expression of mutant con-
struct in 293T cells. d) Sequencing result of the mutation, mutated residue is highlighted in red.BMC Molecular Biology 2005, 6:22 http://www.biomedcentral.com/1471-2199/6/22
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manually pick from hundreds of output sequences. Fur-
thermore, it is not suitable for nucleotide sequences
longer than 15 bp.
In contrast, SiteFind, automatically translates the input
nucleotide sequence and allows the user to graphically
select which residues to mutate. Furthermore, our win-
dow algorithm enables SiteFind to quickly and efficiently
work with sequences of any length. For each restriction
site, if multiple locations are found, SiteFind only gives
the location closest to the desired point mutation: this
means much less information for the user to parse in
order to choose the best restriction site and sequence.
Although not specifically designed for it, SiteFind could
be used to make translational fusions between two differ-
ent coding sequences. The user can specify that SiteFind
give every location found for each restriction enzyme, and
then run a search on a portion of both sequences. Then,
through manual comparison, the user could select a
restriction site found within both sequences and design
KLF4 K225/229R mutant has a novel NheI restriction site Figure 4
KLF4 K225/229R mutant has a novel NheI restriction site. e) pCS2-KLF4-K225/229R construct diagram. f) NheI / 
EcoRI Restriction digest of both wild-type and successfully mutated plasmid DNA. g) α-Flag Western blot showing expression 
of mutant construct in 293T cells. h) Sequencing result of the mutation, mutated residues are highlighted in red.BMC Molecular Biology 2005, 6:22 http://www.biomedcentral.com/1471-2199/6/22
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the appropriate primers for introducing the necessary
mutations.
Conclusion
SiteFind is a useful tool for performing site-directed muta-
genesis, enabling the user to introduce a novel restriction
site into the mutated nucleotide sequence for use as a
marker of successful mutation. The "moving window" is a
novel algorithm that enables SiteFind to work efficiently
with sequences up to 400 bp. In order to demonstrate its
utility, we introduced a point mutation, R390S, into the
wild-type sequence of KLF4 while simultaneously intro-
ducing a novel BglII  restriction site. This mutant DNA
could be cut by BglII, as expected, and expressed a full-
length protein in 293T cells. For a double point-mutation,
K225/229R, we introduced a novel NheI restriction site.
This mutant DNA could be cut by NheI, as expected, and
expressed a full-length protein in 293T cells.
Materials and methods
Materials
pCS2-Flag-KLF4 was sub-cloned from pMT3-KLF4, kindly
provided by Dr. Vincent Yang, and verified by sequencing
(MCLab, San Francisco, CA). All restriction enzymes and
ligase were obtained from New England BioLabs (Ips-
wich, MA). Anti-Flag monoclonal antibody (m2) was pur-
chased from Sigma (St. Louis, MO).
Mutant preparation
SiteFind identified a potential BglII sequence overlapping
with our desired R390S mutation of the KLF4 wild-type
sequence [GenBank: BC010301]. Using the primer design
guidelines included in the QuikChange II Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA), we chose for-
ward primer 5'-CCAAAGAGGGGAAGATCTTCGT-
GGCCCCGG and reverse primer 5'-
CCGGGGCCACGAAGATCTTCCCCTCTTTGG (BglII
restriction site underlined). All primers were synthesized
by Sigma-Genosys. PCR was performed using the Pfu
Turbo DNA Polymerase (Stratagene, La Jolla, CA) accord-
ing to manufacturer's instructions. The PCR product was
then digested with DpnI to remove template DNA, fol-
lowed by transformation of XL-10 competent bacteria.
Bacteria were then plated on ampicllin-containing Luria-
Bertani (LB) agar overnight at 37°C. Individual colonies
were then grown in LB/Ampicillin medium for 12 hours
at 37°C, and plasmid DNA was extracted using the
Qiaprep Miniprep Kit (Qiagen, Valencia, CA). Purified
DNA was then digested with BglII and ClaI and then run
on an 0.8% agarose gel for 30 min at 120 V. Successful
mutants, as determined by the presence of a second, 1244
bp band were grown in 100 mL LB/Ampicillin overnight
and plasmid DNA extracted using the Qiagen Midiprep
Kit (Qiagen, Valencia, CA). Purified DNA was then veri-
fied by sequencing. For our second mutant construct,
K225/229R, SiteFind identified a potential NheI
sequence. For this mutation, we chose forward primer 5'-
CTGATGGGCAGGTTTGTGCTGAGGGCTAGCCTGAC-
CACCCCTGGC and reverse primer 5'-
GCCAGGGGTGGTCAGGCTAGCCCTCAGCACAAACCT-
GCCCATCAG (NheI restriction site underlined). We used
similar methods to produce this construct, except that suc-
cessful mutants were identified by restriction digest with
NheI and EcoRI instead, which yields a 767 bp band.
Cell culture and western blot
HeLa and 293T cells were grown in DMEM media supple-
mented with 10% FBS and 1% penicillin/streptomycin,
and split as needed. For Western blot, 293T cells were
plated on a 12-well plate and transfected with 1ug of
either pCS2 empty vector, pCS2-Flag-KLF4, pCS2-Flag-
KLF4-R390S, or pCS2-Flag-KLF4-K225/229R using the
calcium phosphate method. After 6 hours, the media was
replaced and the cells allowed to grow for another 36
hours. Cells were lysed in standard RIPA buffer with 1%
Triton X-100 and protease inhibitor cocktail. Lysate was
boiled in SDS sample buffer and run on a 10% polyacry-
lamide gel at 180 V for 45 min, and transferred to an
Immobilon membrane (Millipore, Billerica, MA) at 30 V
overnight. After blocking in TBS-T with 5% milk for 1 hr,
membrane was incubated with α-Flag primary antibody
(1:1000) for 1 hr, washed, and incubated with α-mouse
secondary antibody (1:10,000). Membrane was then visu-
alized using ECL buffer and exposed to X-ray film.
Availability and requirements
Project name: SiteFind
Project home page: http://www.utmb.edu/scccb/soft
ware/sitefind.html
Operating system: Platform independent (any system
with Java installed)
Programming language: Java
Other requirements: SiteFind is freely available to both
academic and commercial users as a webpage-embedded
Java applet.
Source code: Available at http://bioinformatics.org/
project/?group_id=533
List of abbreviations used
bp: base pair
DNA: Deoxyribonucleic acid
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kb: One thousand nucleotide bases
PCR: Polymerase chain reaction
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